Mario Chan, MD
Endocrinology, Diabetes & Metabolism · Arlington Heights, ILNPI 1104975176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 1,328 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,328 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$4K
- Dexcom, Inc.$3K
- Boehringer Ingelheim$3K
- Amgen$2K
- Novo Nordisk$2K
- Corcept Therapeutics$2K
- plus $17K from 54 others
What the payments were for
- Food & beverage$31,79098%
- Education$5242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$925
- Rayaldee$508
- Korlym$485
- Prolia$372
- Vascepa$349
- FREESTYLE LIBRE 3$266
- TZIELD$257
- NEXLIZET$245
- NEXLETOL$245
- TEPEZZA$241
- Kerendia$232
- DEXCOM G6 TRANSMITTER$174
- MINIMED 770G$147
- CeQur Simplicity$135
- CRENESSITY$134
- Omnipod$128
- TOUJEO$125
- ISTURISA$125
- Wegovy$125
- Tymlos$121
How this compares
$32,314 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Signifor LarPasireotide Pamoate | 11 | $203,815 |
| OzempicSemaglutide | 118 | $188,081 |
| JardianceEmpagliflozin | 113 | $166,049 |
| FarxigaDapagliflozin Propanediol | 61 | $90,039 |
| SomavertPegvisomant | 12 | $89,921 |
| MounjaroTirzepatide | 57 | $88,648 |
| TrulicityDulaglutide | 54 | $81,325 |
| RybelsusSemaglutide | 31 | $66,649 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $64,880 |
| JanuviaSitagliptin Phosphate | 39 | $64,296 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $43,349 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $36,314 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $31,669 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $26,720 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $24,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,812 | $265,098178 claims |
| Recordati_rare_diseases_inc.Signifor Lar | $429 | $203,81511 claims |
| Lilly USA, LLCMounjaro, Trulicity | $3,876 | $169,973111 claims |
| Boehringer IngelheimJardiance | $2,615 | $166,049113 claims |
| AstraZenecaFarxiga | $1,389 | $90,03961 claims |
| MerckJanuvia, Janumet Xr | $419 | $81,10650 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,310 | $31,66923 claims |
| Mannkind CorporationAfrezza | $1,026 | $20,20511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $875 | $6,316503 claims |
| AbbVieSynthroid | $380 | $4,85858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Arlington Heights
- Daniel SoArlington Heights$283K
- Luis SorucoArlington Heights$27K
- Zubair IlyasArlington Heights$16K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.